Hepatitis C Virus( HCV) Infection affects approximately 170 million people globally,that causes chronic hepatitis C and has been associated with cirrhosis and hepatocellular carcinoma. In the past few years,significant advances have been made in development and clinical application of direct anti-viral agents( DAA) that have been demonstrated highly safe and effective with very high sustained virological response( SVR) rates. This article provides systemic review in this field,especially USA FDA approved DAA regimens for HCV treatment.
DownLoad: